Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Revelation Biosciences Inc. (REVB) stock has hit a 52-week low, trading at $2.71, as the company faces a challenging period marked by a significant downturn over the past year. According to InvestingPro data, while the company maintains a healthy current ratio of 3.43 and holds more cash than debt, it’s quickly burning through available resources with negative free cash flow of -$18.34M. The stock’s current price level reflects a stark contrast to its performance over the last 12 months, with Revelation Biosciences witnessing a precipitous 1-year change of -91.11%. This substantial decline has raised concerns among investors as they evaluate the company’s prospects and the broader implications for its sector. InvestingPro analysis suggests the stock is currently undervalued, though investors should note that analysts don’t expect profitability this year. For deeper insights into REVB’s financial health and 11 additional ProTips, consider exploring InvestingPro.
In other recent news, Revelation Biosciences, Inc. has implemented a reverse stock split of its common stock. Effective as of January 28, 2025, the company consolidated every sixteen shares of issued and outstanding common stock into one share. This move was approved by the board of directors and stockholders, and aims to enhance the marketability and liquidity of the company’s shares. Following the reverse stock split, approximately 522,281 shares of common stock remain outstanding. No fractional shares were issued, with stockholders receiving the nearest whole share. Concurrently, Revelation Biosciences adjusted all outstanding equity awards and warrants proportionally, except for certain warrants with price reset features. The company’s equity incentive plans were also modified to align with the new share structure. This development was detailed in a recent 8-K filing with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.